Health Care Blog November 2, 2020
Ceci Connolly, Bobby Clark

We are all are anxiously awaiting the approval and delivery of a cure to the novel coronavirus – or better yet, a vaccine.

Amid the race to develop a safe and effective vaccine, some may be inclined to give drug companies a pass on their well-established bad behavior related to pricing and market competition.

But that would be an awfully expensive mistake.

As the COVID-19 pandemic claims more lives and families’ livelihood, policymakers and the public must press drug makers for more information on the products they are developing. The country must be protected against price-gouging for therapies that could bring the pandemic to a halt.

Yes, we need America’s biopharmaceutical companies to develop a cure or vaccine so we...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Govt Agencies, Healthcare System, Patient / Consumer, Pharma / Biotech, Precision Medicine, Pricing / Spending, Provider, Public Health / COVID
Global medical costs to increase by double digits for third straight year, survey finds
Healthcare Costs Are Devouring The Earnings Of Middle-Class Families
Another year, higher healthcare prices: Are employers ready for 2025?
Healthcare’s Cost Crisis: How Primary Care Can Deliver The Savings We Need
Are hospitals complying with price transparency rules? What an OIG report found.

Share This Article